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a b s t r a c t
Background: To date, few large-scale comparative effectiveness studies of influenza vaccination have
been conducted in Japan, since marketing authorization for influenza vaccines in Japan has been granted
based only on the results of seroconversion and safety in small-sized populations in clinical trial phases
not on the vaccine effectiveness. We evaluated the clinical effectiveness of influenza vaccination for
children aged 1–15 years in Japan throughout four influenza seasons from 2010 to 2014 in the real world
setting.
Methods: We conducted a cohort study using a large-scale claims database for employee health care
insurance plans covering more than 3 million people, including enrollees and their dependents.
Vaccination status was identified using plan records for the influenza vaccination subsidies.
The effectiveness of influenza vaccination in preventing influenza and its complications was evaluated.
To control confounding related to influenza vaccination, odds ratios (OR) were calculated by applying a
doubly robust method using the propensity score for vaccination.
Results: Total study population throughout the four consecutive influenza seasons was over 116,000.
Vaccination rate was higher in younger children and in the recent influenza seasons. Throughout the four
seasons, the estimated ORs for influenza onset were statistically significant and ranged from 0.797 to
0.894 after doubly robust adjustment. On age stratification, significant ORs were observed in younger
children. Additionally, ORs for influenza complication outcomes, such as pneumonia, hospitalization with
influenza and respiratory tract diseases, were significantly reduced, except for hospitalization with influ-
enza in the 2010/2011 and 2012/2013 seasons.
Conclusions: We confirmed the clinical effectiveness of influenza vaccination in children aged 1–15 years
from the 2010/2011 to 2013/2014 influenza seasons. Influenza vaccine significantly prevented the onset
of influenza and was effective in reducing its secondary complications.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Because children are considered the primary infection center of
influenza epidemics in the community, influenza vaccination,
especially in the group aged less than 6 years, is recommended
by WHO [1–4]. Influenza vaccination for children has been shown
to effectively prevent the onset and spread of influenza by
establishing herd immunity [5]. Currently, although influenza
vaccination is highly recommended in Japan for school-aged
children, it is available only through medical institutions on a
voluntary basis at the vaccinees’ own expense. Some employee
health insurance plans subsidize influenza vaccination in children,
especially in those aged under 16 years.
Although large-scale studies of the effectiveness of influenza
vaccination have been conducted in many countries [6–9],
evidence generated from large-scale studies using the vaccines
available in Japan is lacking. Only inactivated, non-adjuvanted
products are manufactured by a limited number of domestic
suppliers, and supply is controlled under the Health Authority’s
vaccine policy [10]. Marketing authorization for influenza vaccines
in Japan is normally granted based on the results of seroconversion
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and safety in small-sized populations in clinical trial phases. These
marketing authorization holders of influenza vaccines have long
been reluctant to submit clinical evidence affirming the effective-
ness of vaccination. From a public health perspective, it is therefore
essential to evaluate the clinical effectiveness of vaccination in the
post-marketing stage. Partly due to the absence of a nationwide
vaccine registry, no large-scale effectiveness study of childhood
influenza vaccination has yet been reported in Japan, although
some hospital- or community-based studies have been reported
[11,12].
Here, we evaluated the clinical effectiveness of influenza vacci-
nation for children in Japan across four influenza seasons using a
large-scale claims database.
2. Methods
2.1. Study design and population
We conducted a cohort study using a large-scale claims data-
base which covered more than 3 million enrollees of employee
health care insurance plans and their dependents, and contained
enrollee claims records for ambulatory care, hospitalization and
pharmacy benefits. The database was provided by JMDC (Japan
Medical Data Center Co., Ltd., Tokyo, Japan) [13]. The present
subjects were children aged 1–15 years who were the dependents
of employees covered by the health plans and eligible for the insur-
ers’ vaccine subsidiary programs. Total study duration covered four
consecutive influenza seasons, from October 2010 to May 2014.
Influenza season for the analysis was determined to extend from
October 1, the start date of influenza vaccination at medical insti-
tutes in Japan for each year according to the Health Ministry’s
policy, to the following May 31, when less than one influenza case
per week per sentinel site on national average was reported after
the peak, according to the weekly reports of infectious diseases
published by the National Institute of Infectious Diseases [14,15].
Before data were retrieved from the health plan databases and
transferred to the JMDC claims database, all identifiable personal
data were anonymized and study subjects were coded with a
unique identifier. Ethical approval for the study and waiver of
informed consent by study subjects were obtained from the Ethics
Committee of Kyoto University Graduate School and Faculty of
Medicine (No. E-1822).
2.2. Outcome definition
The primary outcome was the effectiveness of influenza vacci-
nation in preventing the onset of influenza. For this, a diagnosis
of influenza was based on the International Statistical Classifica-
tion of Diseases and Related Health Problems 10th Revision (ICD-
10) codes (J101, J110, J111 and J118). To test the robustness of
influenza diagnosis, sensitivity analyses were performed using
three different outcome definitions for influenza occurrence: (1)
combination of the above defined ICD-10 codes with records for
the use of a rapid-testing kit; (2) combination of these ICD-10
codes with the prescription of antiviral drugs; or (3) combination
of the J101 code ‘‘influenza due to identified seasonal influenza
virus” with the use of a rapid-testing kit [16]. Antiviral drugs were
determined using the Anatomical Therapeutic Chemical J05B4
classification of the European Pharmaceutical Marketing Research
Association: laninamivir, oseltamivir, peramivir and zanamivir,
and use of a rapid testing was identified by claim records for the
influenza virus antigen (High-sensitive) test.
The secondary outcome was the effect of influenza vaccination
on complications of influenza infection. Patients with diagnosis
codes for pneumonia (J12-J18) and respiratory tract diseases
(RTD: J00-J22, except for the above codes for influenza) were iden-
tified. Hospitalized cases met the following criteria: hospitalized
within three days before or after the date of influenza diagnosis
(hospitalization with influenza); and hospitalized within seven
days after the diagnosis date of RTD (hospitalization with RTD).
2.3. Influenza vaccination
Seasonal trivalent inactivated, non-adjuvanted influenza vacci-
nes were available for children aged 6 months or older during
the study period in Japan. Influenza A(H1N1pdm09) was the most
prevalent circulating strain in the 2010/2011 (52%) and 2013/2014
(43%) seasons, and A(H3N2) was the most prevalent circulating
strain in the 2011/2012 (71%) and 2012/2013 (76%) seasons [15]
(Table 1). Antigenic characteristics of vaccine strains are shown
in Table 1. The dose of vaccine for children aged under 13 years
was increased from the 2011/2012 season to be equivalent to the
world standard dose (Appendix 1). Vaccination status and dates
were identified from the records for influenza vaccination
subsidies of the health plan. Subjects who were vaccinated after
the onset of an outcome of concern were censored at the time of
outcome diagnosis and classified as non-vaccinees.
2.4. Confounding factors
Covariates considered for adjustment of potential confounders
were influenza vaccination status in the immediately preceding
season, age group (low-age group, 1–5 years old; high-age group,
6–15 years old), sex, the presence of siblings aged 0–15 or over
15 years, preceding onset of influenza among siblings aged 1–15
years during each influenza season, a history of high-risk medical
conditions, emergent hospitalization, and number of outpatient
visits during or out of office hours in the preceding influenza off-
season (June to September). High-risk medical conditions were
defined in accordance with the definition of the US Center for Dis-
ease Control and Prevention [17]. Siblings were identified by hav-
ing the same insurance number for dependents. ‘‘Preceding onset
of influenza among siblings” was defined as the risk of second
infection to which a subject was exposed when his/her siblings
aged 1–15 years had had any influenza diagnosis code prior to
his/her first influenza occurrence, or during the influenza season
in the case of no occurrence; this was considered only in the anal-
yses of the primary outcome and in the secondary outcome for
hospitalization with influenza.
2.5. Statistical analysis
Subject characteristics during the four seasons were summa-
rized with descriptive statistics. Comparison of continuous
variables between vaccinees and non-vaccinees was tested with
the Mann-Whitney test. The chi-square test was used for compar-
ison of categorical variables.
The primary analysis was odds ratios (ORs) of outcome events
for influenza vaccination, with a lower OR indicating better
effectiveness. First, ORs for influenza vaccination and other
covariates were calculated by conventional multivariate logistic
regression for whole subjects and age groups. Next, a doubly
robust method (DR) using inverse probability treatment weight-
ing (IPTW) by propensity score (PS) was applied to calculate the
ORDRs to adjust confounding related to influenza vaccination
[18,19]. Whether to be vaccinated is known to be strongly
associated with health-seeking behaviors, and PS implementation
has an advantage in adjusting the channeling bias that health-
seeking behaviors involve [20,21]. However, it is known that
PS adjustment methods yield biased estimates when the model
used to specify the PS is misspecified, and the IPTW estimator
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may then be biased. DR incorporates regression model of out-
comes into IPTW, which can provide unbiased estimators if
any one of these modellings fits [22,23]. The PSs were calculated
for ORDRs as the probability of being vaccinated in the current
season. Covariates considered in calculating the PSs were the
above-mentioned variables, except for preceding onset of influ-
enza among siblings aged 1–15 years. C-statistics were calcu-
lated and the Hosmer-Lemeshow test was conducted for
validity of PSs. Vaccinees with PS < 0.1 and non-vaccinees with
PS > 0.9 were excluded from the primary analysis. Since their
vaccination status was in fact contrary to that predicted by the
estimated PSs, subjects with such extreme PSs would have been
excessively weighted with the inverse of PSs and could have
been highly influential in causing bias if they had been included
in the IPTW analysis. Excessive weighting warranted the trim-
ming of these subjects to eliminate bias [24].
Cox proportional hazard survival function with vaccination and
preceding onset of influenza among siblings as a time-dependent
covariate was applied to estimate the hazard ratios for influenza
onset as a secondary analysis. A potential bias which induces
greater apparent vaccine effectiveness has been reported for
elderly mortality studies using electronic health record databases
[27–29]. We examined this bias by applying a Cox-hazard model
in a pre-epidemic period with minimum influenza circulation,
defined as follows: the start date was October 1st, and the end date
was the day before the beginning of the 1st week when more than
one influenza case per sentinel site on national average was
reported for each season [15].
Subjects who had a defined outcome within 13 days after vacci-
nation were excluded from the primary and secondary analyses
because of potentially incomplete vaccine-induced protection
[9,25,26].
Statistical analyses were performed using SPSS version 22.0
(IBM Corp., Armonk, NY) and SAS version 9.1 (SAS Institute). All
tests were 2-tailed with a significance level of 0.05.
3. Results
The total study population throughout the four seasons was
over 116,000. For primary analysis, over 26,000 children were
included in every season, after excluding a total of 529 children
with extreme PSs or with the onset of an outcome within 13 days
after their vaccination date. Vaccination rate differed by age and
year of influenza season; it was higher in the low-age group and
in the later years (Fig. 1). Annual vaccination rate gradually
increased with statistical significance; 41.8% (2010/2011 season),
44.8% (2011/2012), 50.6% (2012/2013), and 51.3% (2013/2014)
(chi-square test, p < 0.001). Characteristics were similar among
the four seasons, whereas those between vaccinees and non-
vaccinees were significantly different in every season (Table 2).
Table 1
Antigenic characteristics of vaccine strains and influenza viruses in the 2010 /2011 to 2013/2014 influenza seasons in Japan.
Influenza season and type or subtype Vaccine component Circulating strain
2010/2011
H1N1pdm09 (52%)a A/California/7/2009pdm A/California/7/2009pdm-like
H3N2 (32%) A/Victoria/210/2009 A/Victoria/210/2009-like or
A/Perth/16/2009-like




H1N1pdm09 (0.2%) A/California/7/2009pdm09 A/California/7/2009pdm09-like
H3N2 (71%)a A/Victoria/210/2009 A/Victoria/361/2011-like




H1N1pdm09 (2%) A/California/7/2009pdm09 A/California/7/2009-like
H3N2 (76%)a A/Victoria/361/2011 A/Victoria/361/2011-like




H1N1pdm09 (43%)a A/California/7/2009(X-179A)pdm09 A/California/7/2009-like
H3N2 (21%) A/Texas/50/2012(X-223) A/Texas/50/2012-like





























Fig. 1. Annual vaccination rates by age in Japanese children.
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3.1. Vaccine effectiveness for influenza onset
Current-year vaccination significantly reduced the risk of
influenza onset throughout the four seasons after adjustment for
covariates in logistic regression analysis (Appendix 2). ORs of
influenza onset for current-year vaccination were 0.895 in
2010/2011 (p-value: 0.001), 0.804 in 2011/2012 (<0.001), 0.828
in 2012/2013 (<0.001), and 0.815 in 2013/2014 (<0.001), although
ORs for previous year vaccination were significantly larger than
one except for the 2013/2014 season. Having siblings aged over
Table 2
Characteristics of Japanese children in the primary analysis, stratified by vaccination status in the current influenza season.









Characteristic No. (%) No. (%) P Valuea No. (%) No. (%) P Valuea
Age (median [interquartile range]) 6 [3,10] 7 [3, 11] <0.001y 6 [3, 10] 7 [4, 11] <0.001y
<5 yrs 3806 (34.6%) 4957 (32.4%) <0.001* 4332 (34.8%) 4925 (32.1%) <0.001*
Female 5357 (48.7%) 7401 (48.3%) 0.516* 6019 (48.4%) 7487 (48.8%) 0.538*
Have siblings
Aged 0–15 yrs 9278 (84.4%) 11,594 (75.7%) <0.001* 10,327 (83.0%) 11,645 (75.8%) <0.001*
Aged 16 yrs or older 620 (5.6%) 1732 (11.3%) <0.001* 755 (6.1%) 1794 (11.7%) <0.001*
Vaccination in previous season 6789 (61.7%) 2209 (14.4%) <0.001* 8137 (65.4%) 2571 (16.7%) <0.001*
Before influenza season
Number of outpatient visits
During office hours (median [range]) 6 [0–183] 2 [0–53] <0.001y 6 [0–212] 2 [0–40] <0.001y
Out-of-office hours (median [range]) 0 [0–36] 0 [0–47] <0.001y 0 [0–26] 0 [0–11] <0.001y
Emergent hospitalization 6 (0.05%) 9 (0.06%) 1.000* 5 (0.04%) 10 (0.07%) 0.444*
High-risk condition 2998 (27.3%) 2940 (19.2%) <0.001* 3253 (26.1%) 2998 (19.5%) <0.001*
During influenza season
Preceding onset of influenza among siblings 2140 (19.5%) 2541 (16.6%) <0.001* 2267 (18.2%) 2508 (16.3%) <0.001*









Characteristic No. (%) No. (%) P Valuea No. (%) No. (%) P Valuea
Age (median [interquartile range]) 6 [3, 10] 7 [4, 11] <0.001y 6 [3, 10] 7 [4, 11] <0.001y
<5 yrs 5356 (35.2%) 4639 (31.2%) <0.001* 5732 (35.1%) 4696 (30.4%) <0.001*
Female 7329 (48.2%) 7269 (48.9%) 0.208* 7881 (48.3%) 7535 (48.7%) 0.465*
Have siblings
Aged 0–15 yrs 12,479 (82.1%) 11,351 (76.4%) <0.001* 13,441 (82.4%) 11,677 (75.5%) <0.001*
Aged 16 yrs or older 988 (6.5%) 1725 (11.6%) <0.001* 1083 (6.6%) 1822 (11.8%) <0.001*
Vaccination in previous season 10,054 (66.1%) 2065 (13.9%) <0.001* 12,297 (75.4%) 2511 (16.2%) <0.001*
Before influenza season
Number of outpatient visits
During office hours (median [range]) 6 [0–116] 1 [0–41] <0.001y 6 [0–148] 2 [0–53] <0.001y
Out-of-office hours (median [range]) 0 [0–54] 0 [0–20] <0.001y 0 [0–32] 0 [0–53] <0.001y
Emergent hospitalization 11 (0.07%) 11 (0.07%) 1.000* 7 (0.04%) 9 (0.06%) 0.622*
High-risk condition 3913 (25.7%) 2547 (17.1%) <0.001* 4040 (24.8%) 2758 (17.8%) <0.001*
During influenza season
Preceding onset of influenza among siblings 2294 (15.1%) 2033 (13.7%) 0.001* 2441 (15.0%) 2313 (15.0%) 0.987*
a The v2 test was used for categorical variables (*) and the Mann-Whitney test for continuous variables (y) between vaccinees and non-vaccinees in each influenza season.
Table 3
Incidence of influenza onset and odds ratios (ORDR) for influenza vaccination using multiple outcome definitions in Japanese children by season; doubly robust method.
Influenza season 2010/2011 2011/2012 2012/2013 2013/2014
Outcome definition No. (%) No. (%) No. (%) No. (%)
ORDR (95% CI) ORDR (95% CI) ORDR (95% CI) ORDR (95% CI)
Influenza diagnosis codes onlya 6788 (25.8) 6954 (25.0) 5844 (19.4) 6602 (20.8)
0.894 (0.838–0.950) 0.797 (0.748–0.847) 0.841 (0.788–0.895) 0.821 (0.769–0.873)
Influenza diagnosis codes
+ Prescription of antiviral drugs
6160 (23.4) 6339 (22.8) 5243 (17.4) 5940 (18.7)
0.897 (0.839–0.955) 0.793 (0.742–0.843) 0.849 (0.793–0.905) 0.808 (0.755–0.862)
Influenza diagnosis codes
+ Use of rapid testing
6108 (23.2) 6170 (22.2) 5214 (17.3) 5884 (18.5)
0.911 (0.853–0.970) 0.803 (0.752–0.855) 0.858 (0.801–0.915) 0.815 (0.761–0.869)
ICD10 J101 code
+ Use of rapid testingb
3814 (14.5) 4047 (14.5) 3533 (11.7) 4124 (13.0)
0.889 (0.820–0.959) 0.829 (0.766–0.892) 0.832 (0.767–0.897) 0.811 (0.749–0.873)
For each outcome, we excluded subjects who had the outcome within 13 days after vaccination. Therefore, the number of study subjects in one season differed by outcome
definition. All confounders were adjusted using a doubly robust method.
a Defined by ICD-10 influenza diagnosis codes (J101, J110, J111, J118).
b Defined by combination of ICD-10 influenza diagnosis codes (J101: influenza due to identified seasonal influenza virus) with use of a rapid-testing as outcome.
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15 years and female sex significantly reduced the risk; in contrast,
some confounders such as high-age group significantly increased
the risk of influenza (Appendix 2).
Given that influenza was defined only by ICD-10 codes, the
ORDRs ranged from 0.797 (2011/2012 season) to 0.894
(2010/2011 season) and were significantly reduced throughout
all the seasons after doubly robust adjustment (Table 3). Sensitivity
analysis using the combination of J101 with the use of a rapid-
testing kit gave similar, statistically significant ORDRs, ranging from
0.811 (2013/2014 season) to 0.889 (2010/2011 season). The C-
statistics of the PSs were 0.791 or more and the Hosmer-
Lemeshow test was statistically significant (p-value: <0.001).
Age-stratified ORs were lower in younger children (Appendix
3). However, in children over 8 years, except for those aged 12,
there were no statistically significant ORs in any of the four influ-
enza seasons.
Cox hazard regression also produced significantly reduced haz-
ard ratios showing similar but slightly smaller vaccine effective-
ness overall, compared with the ORs derived from logistic
regression (Appendix 4). No significant, positive vaccine effective-
ness was shown during the pre-epidemic periods throughout the
four seasons (Appendix 5).
3.2. Vaccine effectiveness for influenza-related complications
Reduction in the ORDRs for influenza complications, including
hospitalization with influenza, pneumonia, RTD and hospitaliza-
tion with RTD, were statistically significant, except for insignificant
ORDRs for hospitalization with influenza in the 2010/2011 and
2012/2013 seasons (Table 4).
4. Discussion
Our study confirmed that influenza vaccination was effective in
preventing influenza onset and its complications such as pneumo-
nia in a post-marketing real world setting, as previously reported
[6,11,30,31]. Given the similar ORs yielded by sensitivity analysis
of the primary outcome, these study results of influenza preven-
tion appear to be robust. Although all the estimated ORs were sig-
nificant, there were variations in the estimated ORs with
outcomes; the reductions in ORs for influenza onset were modest
while the reductions in ORs for influenza complications were
substantial.
Of note, vaccine effectiveness estimated with the ORs for influ-
enza onset was lower than our expectation. Modest effectiveness
was also reported in other studies, especially in older children,
albeit that these were higher than in our study [11,31]. Several
plausible reasons include use of less specific outcome definitions
employing claims records rather than laboratory-confirmed diag-
nosis and a lack of herd immunity at school. Use of PCR for over
26 thousand cases around Japan to identify laboratory-confirmed
influenza is too costly and resource-consuming. Instead, we con-
firmed robustness of the risk estimates in the present study by dif-
ferentiating the outcome definitions for influenza occurrence.
Compared with the approximately 50% vaccination coverage nec-
essary to establish herd immunity in schools [7], coverage was
lower in many of our present age groups. Furthermore, the local
communities to which our study subjects belonged and their vac-
cination status were not specified, since the study was not
population-based. A lower vaccination rate would be expected in
families not covered by a vaccine subsidiary program, possibly
leading to even lower immunity in the community than that
observed in this study.
The PS was calculated using several proxies of health-care seek-
ing behavior including influenza vaccination status in the immedi-
ately preceding season. Given the high values of C-statistics, the
estimated PSs were considered to be valid [32,33]. Owing to the
very large sample size, however, all of the Hosmer-Lemeshow tests
indicated statistical significance between the observed and model-
predicted treatment allocation. Because PS directly considers the
bias related to exposure, which regression models are only able
to adjust indirectly, PS implementation was considered preferable
for adjusting bias due to healthcare seeking behaviors [20,21]. The
DR method adjusts for both direct and indirect confounders via
vaccination status and therefore provides better estimates, but
tends to result in larger variance [33]. Waning effectiveness of
inactivated influenza vaccines indicated potential difficulty in
applying Cox proportional hazard model which do not assume
time-varying efficacy of vaccines, and therefore we used semi-
parametric methods for the primary analysis [34].
Further, the use of a claims database for employee insurance
with excellent traceability of enrollees also allows us to capture
the enrollees without flu-related symptoms or diseases requiring
medical encounters after vaccination. Inclusion of such subjects
in the analysis would be advantageous in the interpretability of
the results by practitioners as well as the public, including health-
care payers, policy makers and insurance enrollees. The absence of
Table 4
Incidence of influenza complications and odds ratios (ORDR) for influenza vaccination in Japanese children by season; doubly robust method.
Influenza season 2010/2011 2011/2012 2012/2013 2013/2014
Outcome No. (%) No. (%) No. (%) No. (%)
ORDR (95% CI) ORDR (95% CI) ORDR (95% CI) ORDR (95% CI)
Hospitalization with influenzaa 42 (0.2) 22 (0.1) 16 (0.1) 27 (0.1)
0.636 (0.186–1.087) 0.388 (-0.027–0.803) 1.651 (-0.214–3.515) 0.290 (0.003–0.577)
Pneumoniab 411 (1.6) 1101 (4.0) 981 (3.3) 706 (2.2)
0.626 (0.478–0.774) 0.591 (0.507–0.674) 0.426 (0.361–0.491) 0.541 (0.445–0.636)
Respiratory tract diseasesc 18,538 (73.3) 20,089 (74.8) 20,849 (72.0) 21,418 (70.2)
0.625 (0.587–0.664) 0.631 (0.593–0.669) 0.580 (0.548–0.612) 0.544 (0.515–0.573)
Hospitalization with respiratory tract diseases d 299 (1.1) 385 (1.4) 301 (1.0) 289 (0.9)
0.661 (0.475–0.848) 0.714 (0.547–0.881) 0.593 (0.435–0.750) 0.519 (0.376–0.661)
For each outcome, we excluded subjects who had the outcome within 13 days after vaccination. Therefore, the number of study subjects in one season differed by outcome.
All confounders were adjusted using a doubly robust method. Preceding onset of influenza among siblings was included only for the analysis of ‘‘hospitalization with
influenza” outcome.
a Hospitalization started within 3 days before or after the data of influenza diagnosis codes.
b Pneumonia including the ICD-10 codes: J12-J18.
c Respiratory tract disease including the ICD-10 codes: J00-J22 except for influenza diagnosis codes, J10 and J11.
d Hospitalization started within 7 days after diagnosis of respiratory tract diseases other than influenza.
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the bias reported in several elderly mortality studies was
suggested by the lack of a significant positive estimate during
the pre-epidemic periods in the present study, as reported in
another database study [35].
Sensitivity analysis using different outcome definitions pro-
vides important insights into the validity of study results. Since
the study database did not provide laboratory-confirmed influenza
diagnoses, a less stringent criterion using the ICD10 codes only was
applied. This is likely to capture the incidence of both influenza and
influenza-like illness. In contrast, use of the J101 code in combina-
tion with a rapid-testing kit may provide the most conservative
estimate of incidence, albeit that it may possibly also lead to an
increase in the number of false-negative cases; this is because
the sensitivity of available rapid-testing kits is approximately
60%, and testing in clinical settings is frequently negative in the
early stage of influenza infection even in true-positive cases [36].
Effectiveness of vaccination varied in degree between the
2010/2011 and 2011/2012 seasons, probably reflecting the dose
change. The dose of vaccine increased in the 2011/2012 season
to an equivalent dosage to Western countries, with the total dose
more than doubling in children aged 3–5 (0.4–1.0 ml; Appendix
1). Antigenic mismatch of vaccines with circulating strains
occurred in the 2011/2012 season: the main circulating strain
was H3N2 (A/Victoria/361/2011-like), which slightly differed from
the vaccine component (A/Victoria/210/2009, Table 1) [37]. How-
ever, this seems to have not substantially affected vaccine effec-
tiveness in the 2011/2012 season, as indicated by the significant
ORs and HR for influenza onset and complications.
Significantly lower ORs for the onset of influenza were observed
in younger children, particularly those aged 1–5 years (Appendix
3), in agreement with a previous study [11]. In contrast, insignifi-
cant ORs were frequently found in the higher aged children. A pos-
sible explanation might include the small sample size after age
stratification.
Several risk factors for the onset of influenza were detected,
including prior season vaccination during the three consecutive
seasons and the presence of siblings aged 0–15 years. Potential
negative effects of repeated vaccination have been reported in
association with the antigenic subtype of epidemic strains and vac-
cine components [38,39]. Due to the lack of antigenic test results, it
is impossible to relate observed increases in the OR for previous
season vaccination with the viral strains and vaccine components;
however, the largest OR for prior season vaccination was found in
the 2012/2013 season, when the H3N2 strain was dominant. Hav-
ing siblings itself seems to increase the chance of exposure to influ-
enza virus by peer contact at home. In contrast, having siblings
aged over 15 years significantly decreased the risk of influenza
onset, although this might have been confounded by the age effect:
that is, children with siblings aged over 15 years were older than
those who did not have such older siblings. In fact, children aged
13–15 years accounted for more than 60% of children having sib-
lings aged over 15 years, versus only around 15% of all subjects.
Because older children had a lower incidence of influenza (data
not shown), children with siblings aged over 15 years appears to
have had a lower risk of influenza onset. Our study is the first to
consider the risk of preceding onset of influenza among siblings.
Although employee insurance numbers helped identify familial
infection, it is impossible to exclude the possibility that children
lived apart from their families, particularly for children of junior
high school age.
Influenza vaccination significantly reduced the risks of several
outcomes related to influenza complications, including pneumo-
nia, underpinning the Japanese health authority’s position state-
ment on influenza vaccination [40].
There were several limitations inherent to the claims database
used in this study. First, given the nature of observational
studies, unmeasured confounders may have remained unadjusted.
Previous studies have reported that observational studies using PS
adjustment might yield larger effect sizes than randomized studies,
and concluded that PS analysis could be relied on only if randomized
studies were impossible, as in the present study including tens of
thousands of children over four consecutive years [41,42].
Second, we used application for an influenza vaccination sub-
sidy as the most reliable proxy for an actual vaccination records.
A few vaccinating enrollees may have failed to apply for subsidiza-
tion, and misclassification of truly vaccinated children as unvacci-
nated is unavoidable, leading to bias towards null. Further, the lack
of data on the number of vaccinations which an individual received
in the same season did not allow us to assess differences in vaccine
effectiveness by the number, because subsidy records for influenza
vaccination were submitted only once per season to most health
plans and did not include the number of vaccinations.
Third, we excluded subjects who had an outcome within 13
days post-vaccination, potentially causing overestimation or
underestimation of ORs. However, this exclusion was in accord
with previous studies [9,25,26].
Fourth, the true reasons for hospitalization could not be speci-
fied, and misclassification of events requiring hospitalization was
unavoidable. Since patients with influenza complications are
sometimes not diagnosed with influenza, we used multiple
definitions.
Finally, while familial or school infection may be responsible for
the risk of secondary infection, such risk remains to be adjusted,
because of the insufficiency and complexity of explanatory
variables.
In conclusion, our analysis confirmed that influenza vaccination
in a large population of children aged 1–15 years significantly pre-
vented the onset of influenza, and may have been effective in
reducing influenza complications such as pneumonia and
influenza-related hospitalizations.
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